Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons? (Q37945301)

25 August 2017

Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons? (English)

1 reference

25 August 2017

0 references

1 reference

6

Zwi Berneman

0 references

Annacarmen Petrizzo

Annacarmen Petrizzo

2

0 references

Evelien Smits

Evelien Smits

3

0 references

Luigi Buonaguro

Luigi Buonaguro

7

0 references

Maria Lina Tornesello

Maria L Tornesello

5

0 references

Nathalie Cools

1

Nathalie Cools

1 reference

25 August 2017

4

Franco M Buonaguro

1 reference

25 August 2017

1 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

3

1 reference

25 August 2017

1203-1222

1 reference

25 August 2017

10

1 reference

Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells.

25 August 2017

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Pathogen recognition and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Translating innate immunity into immunological memory: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

An innately interesting decade of research in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Inferences, questions and possibilities in Toll-like receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Innate signaling by the C-type lectin DC-SIGN dictates immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Self- and nonself-recognition by C-type lectins on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

NOD-LRR proteins: role in host-microbial interactions and inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Heat shock proteins: the fountainhead of innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Natural endogenous adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

CD28/B7 costimulation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic cell-based therapeutic cancer vaccines: what we have and what we need

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic cells and the immunopathogenesis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Rapid dendritic cell recruitment to the bronchial mucosa of patients with atopic asthma in response to local allergen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Cancer vaccine by fusions of dendritic and cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Designing vaccines based on biology of human dendritic cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Role of dendritic cells in HIV-immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Taking dendritic cells into medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Review of human DC subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

The nature of the principal type 1 interferon-producing cells in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Characterization of human blood dendritic cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Cutaneous dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Follicular helper T cells: lineage and location

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Cancer-related inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Inflammatory cell infiltration of tumors: Jekyll or Hyde

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Cytokine regulation networks in the cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Physiology and pathophysiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Interplay of pathogens, cytokines and other stress signals in the regulation of dendritic cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Inflammatory signals in dendritic cell activation and the induction of adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Mechanisms and functional significance of tumour-induced dendritic-cell defects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Tumor-induced modulation of dendritic cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

The dendritic cell-tumor cross-talk in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Altered maturation of peripheral blood dendritic cells in patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Myeloid-derived suppressor cells in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

The suppressive tumor microenvironment: a challenge in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic cell regulation of TH1-TH2 development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Regulatory T cells and mechanisms of immune system control

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Development and function of T helper 1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Signaling pathways in Th2 development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Cell type-specific involvement of RIG-I in antiviral response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Pathogens target DC-SIGN to influence their fate DC-SIGN functions as a pathogen receptor with broad specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Immunosuppression during acute infection with foot-and-mouth disease virus in swine is mediated by IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Hepatitis C Virus Inhibits Cell Surface Expression of HLA-DR, Prevents Dendritic Cell Maturation, and Induces Interleukin-10 Production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Influenza virus evades innate and adaptive immunity via the NS1 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Impaired plasmacytoid dendritic cell innate immune responses in patients with herpes virus-associated acute retinal necrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Role of dendritic cells in antibody-dependent enhancement of dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Self-antigen presentation by dendritic cells and lymphoid stroma and its implications for autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Role of the innate immune system in the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Regulatory T cells--the renaissance of the suppressor T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Regulatory T cells in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Regulatory T cells and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Cutting edge: central nervous system plasmacytoid dendritic cells regulate the severity of relapsing experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Rheumatoid arthritis synovium contains plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

The role of dendritic cells in CNS autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Expression of CCR7 in multiple sclerosis: implications for CNS immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Aberrant phenotype and function of myeloid dendritic cells in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Collagen-specific T-cell repertoire in blood and synovial fluid varies with disease activity in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Experimentally induced recruitment of plasmacytoid (CD123high) dendritic cells in human nasal allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Inhaled allergen-driven CD1c up-regulation and enhanced antigen uptake by activated human respiratory-tract dendritic cells in atopic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic cell subsets in human bronchoalveolar lavage fluid after segmental allergen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Differences in circulating dendritic cell subtypes in pregnant women, cord blood and healthy adult women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Flow cytometrical determination of regulatory cytokines (IL-10, IL-12) and circulating dendritic cell cytokines in allergic asthmatic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Effector and regulatory mechanisms in allergic contact dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

The danger within: endogenous danger signals, atopy and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic cells and airway epithelial cells at the interface between innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Importance of myeloid dendritic cells in persistent airway disease after repeated allergen exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic cells as therapeutic vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Reengineering dendritic cell-based anti-cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

A listing of human tumor antigens recognized by T cells: March 2004 update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Unique human tumor antigens: immunobiology and use in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Translating tumor antigens into cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Targeting the immune system in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic cells and immunity against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Building on dendritic cell subsets to improve cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Clinical considerations in developing dendritic cell vaccine based immunotherapy protocols in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Improving the efficacy of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Cancer immunotherapy by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Twelve immunotherapy drugs that could cure cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Regulation of adaptive immunity by the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Toll-like receptor agonists in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Harnessing human dendritic cell subsets to design novel vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Restoration of anti-human immunodeficiency virus type 1 (HIV-1) responses in CD8+ T cells from late-stage patients on prolonged antiretroviral therapy by stimulation in vitro with HIV-1 protein-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) and CD4(+) T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Anti-interleukin-12 antibody for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

A novel low molecular weight inhibitor of dendritic cells and B cells blocks allergic inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Tolerogenic dendritic cells and the quest for transplant tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Retinoids regulate survival and antigen presentation by immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Tolerogenic dendritic cells: cytokine modulation comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Development of dendritic cell-based immunotherapy for autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Endocytosis mechanisms and the cell biology of antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

A therapeutic dendritic cell-based vaccine for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Therapeutic Immunization with Dendritic Cells Loaded with Heat‐Inactivated Autologous HIV‐1 in Patients with Chronic HIV‐1 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Dendritic Cell-Based Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Differences in circulating dendritic cell subtypes in cord blood and peripheral blood of healthy and allergic children

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.110

21 January 2018

Identifiers

DOI

10.2217/IMT.11.110

1 reference

25 August 2017

1 reference

PubMed ID

21995572